Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

Kentuckiana Cancer Institute

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Non-small Cell Lung Cancer; Extensive Stage Unresectable

Treatments: Drug: Carboplatin; Drug: Docetaxel; Drug: Irinotecan

Study type: Interventional

Funder types: Other

Identifiers

NCT00264134

1047791

CPTAIV-0020-339

Details and patient eligibility

About

Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.

Secondary Objective: To evaluate the dose-related toxicities of this triple regimen in patients with inoperable lung cancer.

Full description

A phase I/II dose escalating study to determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years or older unresectable lung cancer measurable or evaluable lesions Karnofsky PS greater than or equal to 60%

Exclusion criteria

• untreated CNS metastases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)